FMT for Hepatic Encephalopathy? The THEMATIC Trial aims to make is a 'no brainer' [0.03%]
肝性脑病需要FMT？THEMATIC试验旨在使其成为一个'无需思考的问题'
Debbie L Shawcross,Vishal C Patel
Debbie L Shawcross
Benefits of multi-day ex situ perfusion include dampened ischemia reperfusion injury in liver transplantation [0.03%]
多日体外灌流在肝脏移植中的益处包括减轻了缺血再灌注损伤
Florian Huwyler,Matthias Pfister,Jonas Binz et al.
Florian Huwyler et al.
Limitations of Sparse Partial Least Squares in Multiomics: A Critical Analysis of Linear Methods Applied to Nonlinear Biological Data [0.03%]
多组学中稀疏偏最小二乘法的局限性：对应用于非线性生物数据的线性方法进行批判性分析
Yoshiyasu Takefuji
Yoshiyasu Takefuji
Diabetes-Driven Pathophysiological Remodeling of Mesenteric Adipose Tissue: Transcriptomic Insights into Macrophage Infiltration and Adipokine Dyshomeostasis [0.03%]
糖尿病驱动的小肠脂肪组织病理生理重构：转录组学对巨噬细胞浸润和脂联激素失稳态的启示
Zi-Yuan Zou,Yuandi Ma,Cen Xie et al.
Zi-Yuan Zou et al.
Resmetirom directly inhibits lipid accumulation in human liver-derived organoids [0.03%]
雷米替罗直接抑制人肝源类器官中的脂质积聚
Jiajing Li,Ibrahim Ayada,Qiuwei Pan
Jiajing Li
Revisiting the Role of CBL in Liver Fibrosis: Unveiling the Antifibrotic Potential of CBLB inhibitor NX-1607 [0.03%]
重新审视CBL在肝纤维化中的作用：揭示CBLB抑制剂NX-1607的抗纤维化潜力
Kaikai Lu,Yitong Xu,Lei He et al.
Kaikai Lu et al.
Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden [0.03%]
瑞典13,099例与代谢功能障碍相关性脂肪肝疾病的病因特异性死亡率研究
Gabriel Issa,Ying Shang,Rickard Strandberg et al.
Gabriel Issa et al.
Background and aims: Data on cause-specific mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We aimed to determine the rate and risk of death from different causes in patients wit...
Prakash Ramachandran
Prakash Ramachandran
Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury [0.03%]
不同白蛋白治疗时长对肝硬化合并急性肾损伤患者反应率和结局的影响
Eva Maria Schleicher,Henrik Karbannek,Julia Weinmann-Menke et al.
Eva Maria Schleicher et al.
Background and aims: Guidelines recommended volume expansion with albumin for 48 hours for patients with cirrhosis and acute kidney injury (AKI) to correct hypovolemia and rule out prerenal AKI. A recent update in the Acu...